vidupiprant
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2009 (NCT01018550)
Timeline
Indications
Studied for
Mechanism of action
- G protein-coupled receptor 44ANTAGONIST
PTGDR2 antagonist
Indication: Asthma
- Prostanoid DP receptorANTAGONIST
PTGDR antagonist
Indication: Asthma
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)(C)NC(=O)c1ccc(Oc2cc(F)c(CC(=O)O)cc2Cl)c(NS(=O)(=O)c2ccc(C3CC3)cc2Cl)c1- Mol. weight
- 609.5 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1951575 ↗
Also known as
- amg 853
- amg 853
- amg 853
- amg-853
- amg-853
- vidupiprant
- vidupiprant
- vidupiprant
- vidupiprant
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01137565 | Phase 1 | Jun 1, 2010 | Amgen |
| NCT01124279 | Phase 1 | May 1, 2010 | Amgen |
| NCT01018550 | Phase 2 | Oct 1, 2009 | Amgen |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Amgen | For profit | 3 | 3 | 2 | 2009 |
1 organizations
Page 1 / 1